January, 2009 :: Physiological data and clinical outcomes demonstrate that bioidentical hormones are associated with lower risks, including the risk of breast cancer and cardiovascular disease, and are more efficacious than their synthetic and animal- derived counterparts. Until evidence is found to the contrary, bioidentical hormones remain the preferred method of HRT. Further randomized controlled trials are needed to delineate these differences more clearly.

December, 2008 :: Our objective was to determine the relationships between levels of different dietary nutrients intake with circulating endothelial progenitor cells (EPC) and vascular endothelial function in type II diabetic patients. This study demonstrated that daily thiamine intake was positively correlated with the circulating number of EPCs and FMD in patients with type II diabetes, independent of other dietary nutrients intake.

October, 2008 :: A long-standing belief is that higher testosterone (T) will increase the risk of prostate cancer (PCa), yet recent studies do not support this view. The fear that higher T will increase PCa growth stems from a theory of T-dependent PCa growth that originated with observations in a special population (castrated men) that is not particularly relevant to T therapy in hypogonadal men. The negative view of T with regard to PCa should be recognized for what it is--guilt by association.

August, 2008 :: Our results indicate for the first time that vitamin D3 and K1 association is able to modulate in vitro the differentiation towards osteoblastic phenotype of hMSCs derived from fracture sites, thus offering clinicians a promising and low-cost strategy for reparative osteogenesis.

April, 2008 :: Age-related macular degeneration (AMD) predicted stroke and cardiovascular events over the long term in persons aged 49-75 years. This may have potential implications for new intravitreal anti-VEGF AMD therapies.

March, 2008 :: We previously found that the risk of invasive breast cancer varied according to the progestagen component of combined postmenopausal hormone therapy (CHT): progesterone, dydrogesterone, or other progestagens. We conducted the present study to assess how these CHTs were associated with histology- and hormone receptor-defined breast cancer. CONCLUSION: The increase in risk of breast cancer observed with the use of CHTs other than estrogen+progesterone and estrogen+dydrogesterone seems to apply preferentially to ER+ carcinomas, especially those ER+/PR-, and to affect both ductal and lobular carcinomas.

February, 2008 :: This review is dedicated to the role of age-related acquired androgenic deficit in coronary heart disease (CHD) pathogenesis. The analysis of literature show that decrease of testosterone production in males leads to development of dyslipidemia, coronary atherosclerosis, obesity and to increase of blood trombus potential. Thus, androgen deficit potentiates early CHD development in males.

January, 2008 :: Large numbers of hormone replacement therapies (HRTs) are available for the treatment of menopausal symptoms. It is still unclear whether some are more deleterious than others regarding breast cancer risk. The goal of this study was to assess and compare the association between different HRTs and breast cancer risk, using data from the French E3N cohort study. Large numbers of hormone replacement therapies (HRTs) are available for the treatment of menopausal symptoms. It is still unclear whether some are more deleterious than others regarding breast cancer risk. The goal of this study was to assess and compare the association between different HRTs and breast cancer risk, using data from the French E3N cohort study.

May, 2007 :: This observation is in line with the hypothesis that the hormonal status in females modulates the cardiovascular risk and that circulating endothelial progenitor cells (EPCs) could be involved in this phenomenon.

February, 2007 :: A study performed with 77 subjects suggests an inverse correlation between serum DHEAS level and age-related macular degeneration severity scale with a considerably reduced DHEAS level in age-related macular degeneration.